Porous Particles Patent, Lucideon Limited, Apr 2026
Porous Particles Patent, Lucideon Limited, Apr 2026
Genentech Patent - Quaternary Amine ADC Compounds, Apr 2026
The EPO published patent application EP3226909A1 for Genentech, Inc., covering quaternary amine compounds and antibody-drug conjugates (ADCs) thereof. The application, filed under IPC classifications A61K 47/68, A61P 35/00, and multiple C07D chemical classes, designates all current EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Named inventors are John A. FLYGARE, Thomas PILLOW, and Leanna STABEN.
Selective Reduction of Cysteine Residues in IL-17 Antibodies
The European Patent Office published patent application EP3237445A1 by Novartis AG, covering methods for the selective reduction of cysteine residues in IL-17 antibodies. The application names HEITZMANN, Markus and WINKLER, Johann as inventors, with international patent classification codes C07K 16/24 and A61K 39/395. This A1 publication includes the European search report and designates all EU member states plus Switzerland, Norway, and other European Economic Area countries.
Daicel Corporation Osteoclast Differentiation Inhibitor Urolithin EP3756664A1
The European Patent Office published patent application EP3756664A1 for Daicel Corporation on April 15, 2026, covering osteoclast differentiation inhibitor compositions containing urolithin. The inventors are KOBATA Kenji, NAKATANI Sachie, and KUDOH Masatake. The application is classified under A61K 31/37 (phthalide compounds) with designations covering 32 European states including DE, FR, GB, IT, and NL.
Redwood Bioscience Anti-HER2 Antibody-Maytansine Conjugate Patent Application EP3151830A1
The EPO published patent application EP3151830A1 by Redwood Bioscience, Inc. on April 15, 2026, covering anti-HER2 antibody-maytansine conjugates and methods of use for cancer treatment. The application names eight inventors and falls under IPC classifications A61K 47/68 and A61K 31/4045, with potential coverage across 34 European designated states including Germany, France, the United Kingdom, Italy, and Spain.
Agios Crystalline Salt Forms of Quinolinesulfonamide - EP3972957A1
The European Patent Office published application EP3972957A1 on 15 April 2026, covering crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. Agios Pharmaceuticals, Inc. is the applicant, with Lisa M. Grove listed as inventor. The application covers the pharmaceutical compound classified under C07D 215/36, A61P 7/06, and A61K 31/4709, with designated states spanning across European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
AbbVie Inc. - Methods for Treating HCV (EP3125889A1)
AbbVie Inc. filed European patent application EP3125889A1 for methods of treating Hepatitis C Virus (HCV) infection with pharmaceutical compositions classified under A61K 31/454, A61K 31/498, and A61K 31/7072. The European Patent Office published the application on April 15, 2026, establishing a priority date of October 16, 2015. The patent designates all European Patent Convention contracting states, covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
LEO Pharma A/S Pharmaceutical Spray Composition Patent EP2859886A1
The European Patent Office published patent application EP2859886A1 for LEO Pharma A/S covering a pharmaceutical spray composition. The application lists five inventors: Lind, Marianne; Rasmussen, Grit; Sonne, Mette Rydahl; Hansen, Jens; and Petersson, Karsten. The IPC classifications span A61K 9/12 (aerosol compositions), A61K 47/06 (organic compounds), A61K 47/10 (glycols), and A61K 9/00 (pharmaceutical preparations). The application designates 37 European states including major pharmaceutical markets such as Germany, France, the United Kingdom, and the Netherlands.
Compositions for Treating Bone Diseases and Broken Bones, Brigham Young University, EP2755661A1
The EPO published patent application EP2755661A1 for Brigham Young University on April 15, 2026, covering compositions for treating bone diseases and broken bones. The application, classified under A61K 31/575 and related pharmaceutical classes, designates 35 European states including AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, HR, HU, IE, IT, LI, LT, LU, MC, NL, NO, PL, PT, RO, SE, SI, SK, and SM. Inventors are Carl Genberg and Paul B. Savage.
Qu Biologics Inc. EP3137108A1 Anti-Microbial Immunomodulation
The European Patent Office published EP3137108A1 on April 15, 2026, titled 'ANTI-MICROBIAL IMMUNOMODULATION.' The patent application, filed by Qu Biologics Inc., names inventors Harold David Gunn, Salim Dhanji, and David W. Mullins. The invention is classified under IPC categories A61K 39/108, A61K 39/00, A61P 31/04, and A61P 31/12. Designation extends across all relevant European member states including DE, FR, GB, IT, NL, ES, PL, and 24 others.
Strike Bio RNAi Cancer Treatment, Published 15th Apr
Strike Bio RNAi Cancer Treatment, Published 15th Apr
Phase 1 DISP-10 Trial for Advanced GI Cancers
NIH registered a Phase 1 multicenter open-label study (NCT07544589) evaluating DISP-10, a combination therapy of DV-10 adenovirus and idecabtagene vicleucel (BCMA-directed CAR-T), in adult participants with advanced gastrointestinal cancers including colorectal, gastric, esophageal, and gastroesophageal adenocarcinoma. The trial consists of dose-escalation (Part 1) to establish a recommended dose for expansion, followed by dose-expansion (Part 2) to evaluate safety and efficacy at that dose.
Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study
This study registers a prospective longitudinal investigation examining fatigue predictors in patients diagnosed with Sjögren's disease over a 3-month period at Kahramanmaras Sutcu Imam University Medical Faculty Hospital. The study will collect demographic and clinical data including laboratory results, pressure pain threshold measurements using a digital algometer, and validated questionnaires assessing fatigue, disease activity, symptoms, anxiety, depression, pain catastrophizing, sleep quality, and physical activity at baseline and 3-month follow-up. This clinical trial registration does not create compliance obligations for regulated entities — it is an informational record of planned research.
Observational HPV Testing Study Before Subtotal Hysterectomy
Clinical trial NCT07545525 is an observational study registered on April 22, 2026, evaluating high-risk HPV testing in patients indicated for subtotal hysterectomy. Patients testing HPV-positive will proceed to expert colposcopy and conisation if clinically indicated at the time of hysterectomy. The study screens for cervical cancer and human papilloma virus as co-occurring conditions.
Radiologist-Integrated Finite Element Framework for Acromial Stress in Reverse Shoulder Arthroplasty (NCT07545707)
NCT07545707 is a prospective single-center observational study registered April 22, 2026, examining an approach using high-resolution CT and MRI scans combined with customized finite element modelling to analyze stress on the acromion of patients who have undergone reverse shoulder arthroplasty (RSA) surgery. The study will assess rotator cuff deficiency using Goutallier classification quantified as Cuff Deficiency Index (CDI) to calculate deltoid forces for finite element analysis. Von Mises stresses in specific acromion zones defined by Levy et al. will then be analyzed. The study focuses on patients with Rotator Cuff Injuries and Shoulder Fractures.
Effects of Cistanche Deserticola Supplementation on Anaerobic Exercise Performance and Recovery in Men
A double-blind, randomized, placebo-controlled clinical trial has been registered to evaluate whether 8 weeks of Cistanche deserticola supplementation combined with standardized anaerobic training improves exercise performance, recovery markers, and body composition in young adult men across different athletic training levels. Participants will be assigned to receive either Cistanche deserticola extract or matched placebo while completing the same supervised training protocol, with outcomes assessed via Wingate tests, jump performance, blood lactate, creatine kinase, and hormonal indicators.
Determines Effect of Virtual Glasses on Pain and Anxiety During IUD Application
A randomized controlled experimental study registered on ClinicalTrials.gov (NCT07545850) investigates whether using virtual reality glasses during intrauterine device (IUD) application affects pain and anxiety levels in women. The study, registered as of April 22, 2026, tests two hypotheses: that VR during IUD insertion impacts pain levels (H1-a) and anxiety levels (H1-b). This is an observational healthcare research entry documenting study parameters rather than a regulatory action.
Phase 1b aKLmRNA Trial for Aging, 21 Subjects
A Phase 1b randomized, double-blind, placebo-controlled clinical trial (NCT07544420) evaluating aKLmRNA (AKL003), a novel mRNA-mediated protein replacement therapy formulated in lipid nanoparticles, will enroll approximately 21 subjects with the condition of aging. Subjects will be randomized in a 2:1 ratio (active treatment:placebo), with each receiving two injections of 0.5 mg aKLmRNA or saline placebo. The study is registered on ClinicalTrials.gov as a Phase 1 trial with an April 22, 2026 posting date.
Influence of Genetic Polymorphism on Dose-Dependent Analgesic Response and Safety to Propofol in General Anesthesia
This ClinicalTrials.gov entry registers a new observational study (NCT07543523) investigating how genetic polymorphisms in drug-metabolizing enzymes — CYP2B6, CYP2C9, and UGT1A9 — affect individual patient response to propofol, a widely used intravenous anesthetic. The study will enroll patients undergoing general anesthesia and assess outcomes including induction time, recovery time, and adverse-effect profiles across poor and altered metabolizer phenotypes. Study interventions include Propofol Group and Isoflurane Group assignments, with conditions focused on analgesia.
Phase 2 Brenipatide (LY3537031) Trial for IBS-D, Apr 2026
NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07545759) evaluating subcutaneously administered brenipatide (LY3537031) against placebo in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study will assess tolerability, safety, and efficacy over approximately 35 weeks. No regulatory approval, efficacy finding, or compliance obligation is established by this registry entry.
CAA 2026 Provider-Based Clinic Compliance, Attestations, Medicare Reimbursement
K&L Gates LLP attorneys Limo Cherian, Andrew Ruskin, and Sarah Staples-Carlton analyze the Consolidated Appropriations Act of 2026 and its implications for provider-based departments. The article explains provider-based status, mandatory attestation requirements, and compliance steps hospitals and health systems must take to protect Medicare reimbursement. The episode provides practical guidance on navigating the new regulatory landscape for provider-based clinics.
LDH Confirms First Measles Case in Louisiana for 2026
The Louisiana Department of Health confirmed one case of measles in a pediatric resident of Region 1 (Jefferson, Orleans, Plaquemines, and St. Bernard parishes) on April 22, 2026. The patient, who was partially vaccinated and exposed during international travel, is in isolation and receiving treatment at a Region 1 hospital. Public exposures occurred at two Kenner retail locations on April 17. This is the first measles case reported in Louisiana in 2026, following three cases in 2025.
Areola Preservation in Nipple-Sparing Mastectomy With Nipple Involvement
NIH registered a new pilot clinical trial (NCT07544134) titled 'Areola Preservation in NSM With Nipple Involvement' on ClinicalTrials.gov, with an anticipated date of April 22, 2026. The single-arm, single-center prospective study will enroll women with early-stage breast cancer undergoing nipple-sparing mastectomy, conditionally enrolling them into an areola-preservation protocol only if intraoperative frozen section confirms nipple involvement. The intervention involves nipple removal, immediate second frozen section of sub-areolar tissue, areola preservation if cancer-negative, and immediate nipple reconstruction using a local skin flap.
NCT07545655: Ultrasound-Guided Scalp Block Reduces Opioid Use, Improves Hemodynamic Stability, and Decreases Inflammation in Craniotomy Patients
A registered observational study (NCT07545655, registered April 22, 2026) examined craniotomy patients using a skull pin head holder and found that an ultrasound-guided scalp block reduced perioperative opioid consumption, improved hemodynamic stability, and decreased the inflammatory response. The study falls under ClinicalTrials.gov, a clinical trial registry operated by the National Institutes of Health.
Spectral and Ultra High Resolution CT Systems for Non-Invasive Detection of Myocardial Ischemia: Stress CT Perfusion VS. FFR-CT
ClinicalTrials.gov registered observational study NCT07544277 on April 22, 2026, evaluating Photon Counting Detector (PCD)-CT technology combined with Fractional Flow Reserve derived from CT (FFR-CT) and spectral CT perfusion (CTP) for non-invasive detection of significant coronary artery disease (CAD). The study aims to address limitations of energy-integrating detector CT, where FFR-CT shows suboptimal performance and CTP involves high radiation exposure. Conditions under study include FFR-CT, CT angiography, CT perfusion, and coronary arterial disease.
Parkinson's Dynamic Standing Desk Pilot Study, 12 Sessions
NIH registered a Phase 1 pilot study (NCT07543861) evaluating dynamic standing desk use in Parkinson's disease patients over 12 sessions, each lasting 4 hours. The study tests the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting, with Phase 1 as open-label and Phase 2 as an in-lab randomized controlled trial. This registry entry documents study parameters, condition (Parkinson Disease), and intervention (Dynamic Standing Desk) without imposing compliance obligations.
MG-K10 Phase 3 Trial for Chronic Spontaneous Urticaria, NCT07546487
A new Phase 3 clinical trial for MG-K10 humanized monoclonal antibody injection has been registered on ClinicalTrials.gov under NCT07546487. The multicenter, randomized, double-blind, placebo-controlled study will evaluate efficacy and safety in approximately 300 adult participants with Chronic Spontaneous Urticaria inadequately controlled by second-generation H1 antihistamines. Participants will receive either MG-K10 or placebo via subcutaneous injection.
Rectus Abdominis Muscle Parameters and Postoperative Opioid Consumption in Geriatric Patients
This prospective observational study (NCT07545824) registered April 22, 2026 aims to evaluate the relationship between ultrasound-derived rectus abdominis muscle thickness and thickening fraction and postoperative opioid consumption in geriatric patients undergoing abdominal surgery. Preoperative ultrasonographic measurements will be performed during routine clinical care, and postoperative pain scores and analgesic requirements will be recorded within the first 24 hours. The findings may help improve individualized analgesic strategies by identifying patient-specific predictors of postoperative opioid needs.
Knee Osteoarthritis Neuromuscular Control, NCT07544693
A new clinical trial (NCT07544693) registered on ClinicalTrials.gov will investigate neuromuscular control and motor unit behavior in patients with moderate knee osteoarthritis. The study will examine the effects of moderate-intensity strength training performed with or without an unloading knee orthosis on muscle function, motor unit behavior, and force modulation. The study is listed as having a start date of April 22, 2026.
AI mRS Scoring Validation Study, Stroke, Apr 22
ClinicalTrials.gov study NCT07544927 is an observational trial registered in April 2026 to validate an AI-based automatic scoring system for the Modified Rankin Scale (mRS) in stroke patients. The study compares AI-generated mRS scores against standardized manual assessments performed by trained professionals to evaluate consistency and accuracy. The stated goal is to provide a convenient, efficient, and objective tool for stroke prognosis assessment, reduce subjective variability of manual scoring, and optimize the stroke follow-up workflow. Condition under study: Stroke. Study type: Observational.
Lateral Decubitus vs Supine Position on Postoperative Hypoxemia (NCT07545642)
NIH registered clinical trial NCT07545642 on April 22, 2026, a prospective real-world study comparing lateral decubitus position (Group L) versus supine position (Group S) in patients undergoing painless gastroscopy/colonoscopy, to determine whether lateral positioning reduces the incidence of postoperative hypoxemia. The trial represents a simple, non-invasive, and low-cost optimization strategy under investigation for clinical practice. This is a study registration record only and does not constitute clinical guidance or regulatory approval.
Phase 4 mucosal sIgA response after LAIV nasal spray
A Phase 4 clinical trial (NCT07545564) registered April 22, 2026, will evaluate mucosal-specific sIgA antibody geometric mean titer (GMT) responses and the achievement of 2-fold and 4-fold increases in nasal mucosal sIgA antibodies following administration of a nasal spray Live Attenuated Influenza Vaccine (LAIV). The study includes LAIV and placebo intervention arms and is categorised under the condition of Influenza.
DOH Confirms No Elevated Levels of Pesticides or Metals on North Shore
The Hawaiʻi Department of Health released testing results for floodwater, mud, and sediment samples collected from Oʻahu's North Shore after the March Kona Low storms. All samples showed either no detectable levels or low levels well below any health risk for pesticides, arsenic, lead, mercury, and cadmium. Bacterial contamination including Staphylococcus aureus, E. coli, and Salmonella was previously detected and is consistent with flood conditions; the DOH continues to urge cleanup participants to wear PPE and practice good hygiene.
Collection Device with Valve for Liquid Specimen Patent Granted
The USPTO granted Patent US12605149B2 to Zhongshan Ophthalmic Center of Sun Yat-Sen University on April 21, 2026, covering a collection device with a valve for liquid specimens. The device comprises a reservoir with a sealed cavity under negative pressure, a delivery tube with a valve between inlet and outlet, and a piercing component for tissue access. The patent contains 19 claims and was filed on May 30, 2018 under Application No. 16980417.
Belhaven BioPharma Intranasal Epinephrine Delivery Device Patent
Belhaven BioPharma Inc. received US Patent 12605517B1 on April 21, 2026, titled 'Compositions, devices, and methods for intranasal delivery of dry powder epinephrine.' The patent contains 15 claims and names Scott Lyman and Brian Taubenheim as inventors. The patented compositions include epinephrine with a stabilizing agent (citric acid or salt) and carrier for intranasal dry powder delivery. The patent is assigned under CPC classifications A61M 15/08, A61M 11/003, A61K 9/0043, and A61K 31/137. Belhaven BioPharma now holds enforceable intellectual property rights to this intranasal epinephrine formulation in the United States. Competitors developing similar intranasal epinephrine delivery systems for anaphylaxis or respiratory conditions should conduct Freedom to Operate analyses to assess potential infringement exposure.
NeuroLight Neuroenhancement Patent US12605104B2, Granted Apr 21
The USPTO granted Patent US12605104B2 to NeuroLight, Inc. on April 21, 2026, covering a method of facilitating skill learning or improving task performance through brainwave pattern analysis and targeted stimulation. The patent includes 23 claims under CPC classification A61M 21/00 and names Alexander I. Poltorak as the sole inventor. The application was filed on August 14, 2023, under application number 18233835.
Drägerwerk Patent for Breathing Activity Determination Granted
The USPTO granted US Patent 12605519B2 to Drägerwerk AG & Co. KGaA on April 21, 2026, covering a process and signal processing unit for determining pneumatic indicators for a patient's breathing activity. The patent, with 19 claims, describes technology that generates respiratory signals from measured values and determines two pneumatic indicators describing the activity of different regions of the respiratory system.
Visual Pressure Regulating Catheter Patent - Qingdao Biotech Medical
USPTO granted Patent US12605161B2 to QINGDAO BIOTECH MEDICAL CO., LTD on April 21, 2026, covering a visual pressure regulating catheter with integrated hydraulic dilation balloon, pressure regulating handle, endoscope pressure regulating cavity, and dilation liquid perfusion cavity. The invention enables direct endoscopic observation through the catheter into the dilation balloon. The patent contains 13 claims and lists CPC classifications spanning A61B, A61M, and related medical device categories.
US12605094B2 - Closed Arterial Blood Collection Apparatus
USPTO granted Patent US12605094B2 to MUNE CO., LTD. on April 21, 2026 for a closed type arterial blood collection apparatus comprising a saline bag with first and second ports, an A line, first and second three-way valves, a blood collection unit, and a fluid conveying means. The patent application was filed December 28, 2022 under application number 18270088, with 5 claims and multiple CPC classifications including A61M 5/44 and A61B 5/15.
US12605518B2 Gas Passage for PAP Device with Noise Reduction
USPTO granted Patent US12605518B2 to WALLENBERG UNION LLC on April 21, 2026, covering a gas passage for use in a PAP (positive airway pressure) device with integrated noise reduction components. The patent claims 25 items and was filed on July 19, 2024, under Application No. 18778376. The invention includes a passage casing with air intake and outlet, a chamber for gas flow and accumulation, a blower, and noise reduction elements including a ventilation component, intake pipe, and flexible component.
Boston Scientific Scimed Treatment Agent Delivery System Patent Granted
USPTO granted Patent US12605151B2 to Boston Scientific Scimed, Inc. on April 21, 2026, covering a treatment agent delivery system with 20 claims. The patent protects a medical device including a handle with an actuator, a shaft, an actuation member, a cartridge containing a treatment agent, and a plunger, where movement of the actuator controls delivery of the treatment agent from the cartridge. Inventors are Paul Smith, Travis Henchie, and Peter L. Dayton. The patent application was filed on April 12, 2023, under Application No. 18299161.
CPAP Humidifying Tank Patent, Murata Manufacturing, Granted
USPTO granted patent US12605522B2 to Murata Manufacturing Co., Ltd. on April 21, 2026, covering a CPAP apparatus humidifying tank design with improved flow-dividing and shielding sections. The patent application (18302850) was filed April 19, 2023, and contains 8 claims under CPC classifications A61M 16/00 through A61M 2205/123.
Positive Pressure Breathing Device Patent Granted April 21 2026
USPTO granted Patent US12605521B2 to inventor Hsin-Yung Lin on April 21, 2026 for a breathing equipment device that provides positive pressure gas. The device combines a hydrogen generating device (using water electrolysis), a pressurizing device, a mixing device, an atomizing device, and an output device, all coupled to a gas channel. The patent contains 18 claims and covers methods for generating and delivering hydrogen gas mixed with positive pressure gas for therapeutic applications.
Microneedle Electrical Interface Patent Granted to Biolinq
The USPTO granted Patent US12605100B2 to Biolinq Incorporated on April 21, 2026, covering methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure. The patent describes a microneedle-based electrochemical biosensor structure comprising a substrate, microneedle biosensor, primary and secondary electrically conductive elements, and an electrically insulative annular barrier. The patent application (No. 19258472) was filed July 2, 2025, and contains 26 claims.
Becton Dickinson IV Catheter with Side Port for Blood Draw
The USPTO granted Patent US12605096B2 to Becton, Dickinson and Company on April 21, 2026, covering an integrated intravenous catheter device with a side port enabling simultaneous blood draw and fluid injection. The patent (application 17143979, filed January 7, 2021) contains 17 claims and CPC classifications spanning A61B 5/15, A61M 20/39, and A61M 25/00. Named inventor is Jithendra Kumar Sathyanarayana Naidu. The invention facilitates blood sample collection at the time of catheter insertion by providing separate fluid pathways for drawing blood and injecting fluids via an extension set.
PROTECT Project Advances Early Warning Systems Along South American Bioceanic Corridors
PAHO reported on April 22, 2026 that six South American countries — Argentina, Bolivia, Brazil, Chile, Paraguay, and Peru — reviewed progress on coordinated early warning systems for public health threats along biooceanic corridors. The work, under the PROTECT project (Pandemic Response Optimization Through Engaged Communities and Territories), builds on foundations laid in October 2025 in Asunción, Paraguay, and targets governance, systems interoperability, epidemiological surveillance, laboratory capacities, and workforce development through the end of 2026. The initiative is funded by the Pandemic Fund and implemented jointly by PAHO, the World Bank, and PANAFTOSA/SPV.
Bahamas WHO-Certified for Eliminating Mother-to-Child HIV Transmission
The World Health Organization and Pan American Health Organization certified The Bahamas on April 22, 2026 as having eliminated mother-to-child transmission of HIV, making it the latest Caribbean nation to achieve this milestone. The Bahamas joins 12 countries and territories in the Region of the Americas certified for EMTCT, having met WHO's thresholds of less than 2% mother-to-child transmission rate, fewer than 5 new pediatric HIV infections per 1,000 live births, and 95% or higher coverage for antenatal care, HIV testing, and treatment. The achievement reflects sustained political commitment, universal antenatal care regardless of nationality or legal status, integrated laboratory networks, and multi-month dispensing of antiretroviral medicines.
COSALFA 52 Meets in Guyana, Advancing Foot-and-Mouth Disease Eradication
The 52nd Ordinary Meeting of COSALFA opened in Georgetown, Guyana on April 22, 2026, convening delegates from member countries, international organizations, and private sector representatives to advance the Region's progress toward eradicating foot-and-mouth disease. PAHO Director Dr. Jarbas Barbosa stated via video that the Americas is entering the final stage of eradication, with the inclusion of Venezuela on the WOAH-recognized list as a key remaining objective. Key agenda items included the new 2026-2030 Action Plan of PHEFA, Caribbean emergency preparedness, and the first year of operation of the Regional Antigen Bank (BANVACO).
MBP vs No MBP in Laparoscopic Right Hemicolectomy
A randomized controlled trial (NCT07546565) registered at University Medical Center Ho Chi Minh City will compare mechanical bowel preparation (MBP) versus no MBP in patients undergoing laparoscopic right hemicolectomy with intracorporeal anastomosis for colon cancer. The trial will enroll eligible patients randomly assigned to either group and measure surgical site infection rates within 30 days as the primary outcome, alongside secondary outcomes including anastomotic leakage, postoperative ileus, operative time, and length of hospital stay. Findings aim to clarify whether MBP reduces postoperative infections in this specific surgical context.
Digital Lifestyle Intervention for Migrants: RCT in Sweden
A randomized controlled trial (NCT07545239) will evaluate the feasibility, acceptability, and efficacy of a culturally and linguistically adapted 8-week digital lifestyle intervention targeting migrants with moderate psychological distress in Sweden. Participants (N=240) will be randomized to the digital intervention or a wait-list control receiving a general lifestyle module. Assessments will occur at baseline, post-treatment (8 weeks), 2-month follow-up, and 6-month follow-up.
Tiaozhong-Yiqi Decoction RCT for Substance Withdrawal, 80 Patients
A randomized controlled clinical trial registered on ClinicalTrials.gov (NCT07543809) is evaluating Tiaozhong-Yiqi Decoction (TZYD) for treating substance withdrawal syndrome in 80 patients. The intervention group (n=40) receives 200mL TZYD twice daily for 3 months plus routine care; the control group (n=40) receives routine care only. Primary outcome measures withdrawal syndrome symptom improvement via standardized clinical scale; secondary outcomes include serum neurotransmitter levels (dopamine, norepinephrine, 5-hydroxytryptamine), inflammatory factors (IL-6, IL-1β, TNF-α), BDNF, and quality of life scores (QOL-DA V2.0). The study combines network pharmacology analysis with clinical validation to explore TZYD's potential regulatory mechanism on neuroendocrine and immune systems.
ADHELASKIN for Systemic Sclerosis Skin Assessment (NCT07543679)
A clinical trial (NCT07543679) evaluating ADHELASKIN technology by Tactinnov and École Centrale de Lyon for objective assessment of skin damage in patients with systemic sclerosis has been registered on ClinicalTrials.gov. The trial addresses limitations of the modified Rodnan skin score (mRSS), including inter- and intra-observer variability and limited sensitivity to subtle changes. ADHELASKIN uses an indentation method with ruby-based measurement to quantify rigidity, firmness, and elasticity of skin with improved accuracy. The study will classify patients as diffuse cutaneous or limited cutaneous SSc based on skin fibrosis extent.
Teen Vulnerability to Irritability: Brain and Estrogen Changes (NCT07544966)
NIH registered a Phase 4 clinical trial (NCT07544966) titled "Teen Vulnerability to Irritability: Brain and Estrogen Changes," enrolling 50 female adolescents ages 12-16 at risk of suicide. The randomized, placebo-controlled, cross-over study will test the impact of estradiol (E2) and progesterone (P4) stabilization via continuous combined oral contraceptive (Kurvelo) versus placebo on brain networks associated with irritability over two 8-week treatment arms. Each participant undergoes daily hormone sampling, daily symptom ratings, and neuroimaging sessions across conditions.
Nursing Intervention Based on Stress Adaptation Theory for Patients Undergoing Diabetic Retinal Laser Surgery
A randomized controlled study registered on ClinicalTrials.gov under NCT07544381 evaluates whether a nursing intervention based on stress adaptation theory improves pain trajectory and procedural tolerance in patients undergoing ambulatory retinal laser photocoagulation for diabetic retinal disease. Patients were randomized to receive routine peri-procedural care or routine care plus a structured nursing intervention including a brief treatment pause, guided slow breathing, anticipatory communication, real-time reassurance, and post-procedure observation. Outcomes measured include pain intensity, physiologic responses, procedural cooperation, and adverse events.
Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment
A new observational cohort study (NCT07546448) has been registered on ClinicalTrials.gov, examining the relationship between serum electrolyte levels and contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT). The retrospective study will analyze patients treated between 2018 and 2026, classifying participants based on the presence or absence of CI-AKI per serum creatinine changes, with secondary objectives including 90-day mortality and dialysis dependency evaluation.
Phase 3 Megestrol Acetate Trial for T-DXd-Related Fatigue in Advanced Breast Cancer
ClinicalTrials.gov registered a new Phase 3 interventional study (NCT07543536) on April 22, 2026, evaluating whether Megestrol Acetate administered at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can prevent or alleviate T-DXd-related fatigue in patients with advanced or metastatic HER2+, HER2-low, or HER2-ultralow breast cancer. The trial will compare Megestrol Acetate plus T-DXd against placebo plus T-DXd. The study is sponsored by an unnamed party and is classified as Phase 3.
Prospective Study of Minimally Invasive Hernia Repair, 5-Year Follow-up
NIH's ClinicalTrials.gov registered an observational study (NCT07544238) on April 22, 2026, examining clinical outcomes of minimally invasive (laparoscopic and robotic) hernia repair over a 5-year follow-up period. Adult patients scheduled for elective abdominal wall hernia repair (not inguinal) will be tracked at 2-3 months, 1 year, 3 years, and 5 years post-surgery, with CT imaging at 1 year and as needed for complication suspicion. The study will analyze recurrence rates, intra- and postoperative complications, quality of life, aesthetic outcomes, and pain using standard treatment protocols.
Diaphragmatic Breathing vs Incentive Spirometry for GERD - NCT07544433
Clinical trial NCT07544433 registered on ClinicalTrials.gov evaluates two non-invasive respiratory interventions—diaphragmatic breathing exercise (DBE) and volume-oriented incentive spirometry (VIS)—against standard care in patients with gastroesophageal reflux disease (GERD). The 6-week randomized controlled trial will measure outcomes including GERD symptom scores (GERDQ), esophageal acid exposure time, lower esophageal sphincter pressure, and health-related quality of life (GERD-HRQL). Three groups of participants will undergo baseline and post-intervention assessments with daily symptom and adherence diaries.
Governor Braun Releases First Annual Direct-to-Employer Healthcare Review
The Indiana Department of Health Consumer Services and Healthcare Regulation Commission released its inaugural Direct-to-Employer Healthcare Arrangement Plan Review for calendar year 2025 at the direction of Governor Braun. The report found that all five participating health systems—Ascension St. Vincent, Community Health Network, Franciscan Health, Indiana University Health, and Parkview Health Network—met the statutory benchmark requiring employer-direct plans to remain at or below 260% of Medicare rates. The review provides employers new visibility into hospital pricing and highlights direct-to-employer contracting as a tool for managing healthcare costs.
14 Organizations Join USP Convention Including African Medicines Agency, Egyptian Drug Authority
USP added 14 organizations to its Convention as of Spring 2026, including the African Medicines Agency, Egyptian Drug Authority, Indonesian Food and Drug Authority, and Rwandan FDA, among others. The Convention now comprises over 450 member organizations from more than 50 countries representing science, manufacturing, regulatory, patient advocacy, government, and academia. Convention Members provide input and elect USP's Board of Trustees and Council of Experts, supporting USP's mission to protect and promote health by advancing quality across the lifecycle of medicines worldwide.
US12605286B2 Infant Umbilical Cord Stump Protector
The USPTO granted Patent US12605286B2 to ASO LLC for an infant umbilical cord stump protector comprising a pad positionable proximal to the umbilical cord stump and a fluid-impermeable cover with adhesive, deformable, and peripheral regions that form a protective dome shape. The patent, filed on January 31, 2022 under Application No. 17588842, contains 51 claims and 18 CPC classifications in the A61F medical device category. Assignees and inventors seeking to commercialize similar neonatal care products should conduct freedom-to-operate analyses to avoid potential infringement of this issued patent.
Wound Dressing Patent US12605285B2, HIDRAMED SOLUTIONS
The USPTO granted Patent US12605285B2 to HIDRAMED SOLUTIONS LTD on April 21, 2026, covering a wound dressing device that includes a retaining device for encompassing a portion of the body, a dressing, and a fastening element configured external to the retaining device. The patent application was filed on July 20, 2018, under application number 16637989, and contains 21 claims. The invention also relates to a method of applying the device and a combined dressing and fastening element.
Stryker Variax 2 Locking Screw - Non-Sterile, Lot AM5253
Health Canada has issued a Type II medical device recall for Stryker Gmbh's Variax 2 Locking Screw - Non-Sterile, Lot AM5253 (model/catalogue number 657328). Stryker confirmed that one lot was manufactured without the hexalobular feature required for mating with the associated screwdriver, creating a device incompatibility issue. Healthcare providers who have this product in stock should contact the manufacturer for additional information and next steps.
Baxter Head Positioning Adapter Recall Type I
Baxter Corporation is recalling its Adapter For Head Positioning (Model 1739994) following identification that the device may become loose during patient positioning and unintentionally move when used with side rails of the upper back section H V U on Baxter operating tables. The recall affects three lot numbers—109943587, 109948552, and 109964961—and has been classified as Type I, the most serious recall category. Healthcare facilities using this device should contact Baxter for further information and follow any supplementary instructions issued by the firm.
Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration
A randomized controlled trial (NCT07544667) has been registered on ClinicalTrials.gov to evaluate poly-L-lactic acid (Sculptra), an FDA-approved biostimulant, for the treatment of anterior wall pelvic organ prolapse (stage 2 cystocele) in women. The study will compare intravaginal PLLA injection versus placebo and will investigate safety and preliminary efficacy, including impact on sexual function. The trial plans to enroll women with stage 2 cystocele and follow them to assess whether regenerative biologics can shift prolapse management from surgical reconstruction to tissue regeneration.
Observational Study Sensory Stimulation Brain Function
ClinicalTrials.gov registration NCT07544563 documents an observational behavioral and neurophysiological study examining the effects of controlled sensory stimulation (such as music) on brain function, with the study focusing on three conditions: Epilepsy, Anxiety, and Depression Anxiety Disorder. The study is registered as observational with no stated intervention, indicating it involves passive data collection rather than active treatment administration. This registration provides transparency into ongoing clinical research but creates no compliance obligations for any party.
Ultrasound-Guided Low-Volume Brachial Plexus Block in Supraclavicular Region for Shoulder Reduction in Emergency Department
This NIH ClinicalTrials.gov registry entry documents NCT07544485, a retrospective, monocentric observational study analyzing routinely collected clinical data from an orthopedic emergency department between February 2018 and February 2024. The study evaluates the feasibility, safety, and clinical implementation of low-volume (approximately 5 ml local anesthetic) ultrasound-guided brachial plexus block in the supraclavicular region for adult patients with acute shoulder dislocation. Outcomes assessed include procedural success, block-related complications, and temporal trends reflecting adoption of the technique over time.
Health Web Te@m 1.0 Feasibility Study, Northern Sweden
A feasibility study for Health Web - Te@m 1.0, an interprofessional web-based group intervention supporting healthy ageing, has been registered on ClinicalTrials.gov under identifier NCT07545915. The study will evaluate the intervention's acceptability, implementation potential, adherence rates, and ability to detect outcomes among older adults in primary healthcare settings in northern Sweden. Conditions include Healthy Older Adults, with Health Web Te@m listed as the intervention type.
Adjuvant 5-Fluorouracil Following Thermal Ablation for HPV in Kenyan Women With HIV
This Phase 2 randomized, placebo-controlled clinical trial (NCT07545746) will evaluate self-administered 5% 5-fluorouracil (5FU) cream versus placebo to improve human papillomavirus (HPV) clearance after thermal ablation in women with HIV in Kenya. Participants will self-administer the cream intravaginally once every other week for 12 applications starting four weeks post-ablation, with clinic follow-up through 48 weeks. The trial's hypothesis is that 5FU will increase HPV clearance at 24 weeks and prove safe, well-tolerated, and acceptable in this population.
36-Participant RCT Comparing Low-Dye and Calcaneal Taping for Plantar Fasciitis
A randomized controlled trial (NCT07544732) has been registered under the NIH ClinicalTrials.gov database, enrolling 36 participants with plantar fasciitis to compare Low-Dye taping versus Calcaneal taping over a two-week intervention period. The study will measure pain using the Visual Analogue Scale (VAS), functional ability via the Foot Function Index (FFI), ankle range of motion with a goniometer, and gait analysis, with statistical significance set at p < 0.05. This trial registration represents standard prospective clinical research documentation and does not impose any compliance obligations on regulated entities.
Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis (NCT07543900)
ClinicalTrials.gov registered study NCT07543900 titled 'Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis' evaluating virtual exercise-based interventions for patients with multiple sclerosis (MS). The study identifies conditions including Multiple Sclerosis, Exercise, Physical Therapy, Virtual Reality Exposure Therapy, and Rehabilitation Exercise. MS is described as a chronic neuroimmunological and degenerative disease and one of the leading causes of non-traumatic disability in young adults, with considerable healthcare burden. The trial is part of the ExeRVIEM II project examining high-intensity exercise programs with immersive VR.
PBM Study, Corniche Hospital, 2018-2025, Transfusion Reduction
ClinicalTrials.gov registry entry NCT07544017 describes an observational study conducted at Corniche Hospital assessing Patient Blood Management (PBM) implementation and blood product utilization among obstetric deliveries from 2018 to 2025. The primary objective is to estimate changes over time in mean blood product units transfused per delivery, with a hypothesis that increasing PBM maturity following comprehensive implementation in 2022 will correlate with significant reductions after adjusting for case-mix changes.
Online Family Psychoeducation Trial for First-Episode Schizophrenia
NIH's ClinicalTrials.gov registry has posted a new study (NCT07545941) examining whether a mobile-based family psychoeducation program delivered via LINE application can reduce expressed emotion among family members and improve medication adherence in patients with first-episode schizophrenia. The single-arm trial is listed with an anticipated completion date of April 22, 2026. The registry entry identifies the condition as First-Episode Schizophrenia and specifies the intervention as a mobile-based family psychoeducation program.
Phase 2 JSKN003 Versus Trastuzumab for HER2+ Recurrent/Metastatic Breast Cancer
NIH registered Phase 2 randomized controlled trial NCT07545044 on April 22, 2026, comparing JSKN003 against trastuzumab combined with pertuzumab and docetaxel as first-line treatment for participants with HER2-positive recurrent or metastatic breast cancer who have not previously received systemic therapy for advanced disease. Participants who have undergone one prior endocrine treatment regimen remain eligible for enrollment. The open-label multicenter superiority trial is sponsored by an unnamed pharmaceutical entity and will assess both efficacy and safety endpoints.
$43 Million to Make Local Water Infrastructure Projects Affordable Across New York State
The Environmental Facilities Corporation Board of Directors approved $43 million in low-cost financing and State and federal grants to help New York communities afford water and sewer infrastructure improvements statewide, including lead service line replacement in the City of Utica. Funding recipients span eight regions including the Finger Lakes, Long Island, Mohawk Valley, North Country, and Western New York, with projects addressing watermain replacement, PFAS removal, wastewater treatment plant upgrades, and emergency power facilities.
Hochul Announces $20M for Hospital Energy Efficiency and Electrification
Governor Hochul announced that more than $20 million is now available through NYSERDA's Empire Building Challenge: Hospitals (EBC: Hospitals) program for energy efficiency and electrification upgrades at hospitals in New York State. Individual awards of up to $5 million will be granted for scalable low-carbon solutions including building electrification, electrification readiness, and comprehensive energy efficiency projects achieving significant energy and carbon reductions. Hospitals in disadvantaged communities as defined by the New York Climate Justice Working Group will receive prioritization. Proposals are due September 15, 2026, by 3 p.m.; an informational webinar will be held April 22, 2026, at 10 a.m.